



13794 NW 4th Street
Suite 212
Sunrise, FL 33325
Telephone 954-835-1500
Email: rmadaris@bioheartinc.com

For Immediate Release

**BIOHEART'S PRESIDENT / CEO MIKE TOMAS
HONORED FOR BUSINESS AND COMMUNITY
ACCOMPLISHMENTS**

Sunrise, FL – March 25th, 2013 - Bioheart, Inc. (BHRT.OB) announced today that Mike Tomas, the company's President/CEO was awarded the community leadership award from Florida International University (FIU) at the 12th Annual Torch Awards. This award is presented to an alumni who has demonstrated exemplary service and civic involvement in his community. On FIU's 25th anniversary, the FIU Alumni Association established the Torch Awards to honor successful individuals who have had a positive impact on their profession and the community. The alumni and faculty chosen to receive a Torch Award represent FIU's finest, serving as torch bearers and leaders who inspire.

Mr. Tomas has also been nominated for the 2013 Ernst and Young Entrepreneur of the Year award. Recognized as one of the most prestigious business award programs in the country, the Ernst and Young Entrepreneur of the Year awards celebrate the country's most innovative business leaders.

-MORE-

He has also been awarded the Father of the Year Award from the American Diabetes Association. Since 1999, The American Diabetes Association has partnered with the National Father's Day Council to host the Father of the Year Awards dinner. These men have not only attained success in their chosen field but also demonstrated outstanding strength, commitment and love as a devoted father. Mr. Tomas has carved out time to teach and mature his children to become good citizens and proud members of the community.

Dr. William P. Murphy Jr. Chairman of the Board commented, "Bioheart is fortunate to have someone of Mike's caliber leading our company. His business acumen has been proven time and again throughout his career. He has led his many business ventures to success and I feel confident that Bioheart will be no exception."

Mike Tomas was appointed as Bioheart's President, CEO and a Director on June 19, 2010. For the past 11 years, Tomas served as President The ASTRI Group, an early stage private equity investment company in Florida with an investment in Bioheart. In 2003, he joined Bioheart's Board of Directors as the independent representative of The ASTRI Group. Prior to this, Tomas held ascending executive positions including Chief Marketing Officer at Avantel, a \$1 billion dollar joint venture with MCI. He currently sits on the boards of Perimeter Internetworking, Avisena and Total Home Health. He is also the current chairman of the Global Entrepreneurship Center at Florida International University and a founding coach/mentor at the University of Miami's Launch Pad at the Toppel Center. Mike holds a Masters of Business Administration from the University of Miami, a Bachelor degree from Florida International University and an Associate degree from Miami Dade College.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

###

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2011, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.